BioSpecifics Technologies Corp

BioSpecifics Technologies — Investor Presentation (January 2017)

24 slides from BioSpecifics Technologies's investor presentation, Jan 6, 2017

  1. Slide 1: Innovators in the development & commercialization of injectable collagenase

    ‘eo ‘a? Innovators in the development & commercialization of: INJECTABLE COLLAGENASE @ ara = @ ie BioSpecifics January 2017

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding

  3. Slide 3: Company Overview (NASDAQ: BSTC)

    Company Overview (NASDAQ: BSTC) © So Oo Originator of collagenase based-therapies Positive clinical results for CCH reported in 12 indications to date Profitable biopharma company with lean corporate structure and stock buy-back program Receives revenues from XIAFLEX® milestones, royalties on net sa

  4. Slide 4: Pipeline

    XIAFLEX® Pipeline Cures concur (0 TS jar Pevonids Cee rd > Cellulite endo ie Phase 2b data reported in Nov. Endo is currently performing a commercial assessment BSTC reported positive, statistically Human tipoma endo oo significant Phase 2 topline results in Adhesive Capsulitis endo June 2016; Endo

  5. Slide 5: Marketed XIAFLEX Indications: Dupuytren's Contracture & Peyronie's Disease

    Marketed XIAFLEX Indications: Dupuytren’s Contracture & Peyronie’s Disease

  6. Slide 6: XIAFLEX 3Q16 U.S. Net Sales and Future Growth Initiatives

    XIAFLEX 3Q16 U.S. Net Sales and Future Growth Initiatives 3Q16 U.S. net sales were $47.7 million, a 19% increase vs. 3Q15 FUTURE GROWTH INITIATIVES: Broaden physician base with improved targeting to reach the most appropriate physicians Direct to consumer campaigns Dupuytren’s contracture print ads

  7. Slide 7: Dupuytren's Contracture

    XIAFLEX® for Dupuytren’s Contracture Definition & Key Complications Deforming condition of the hand in which one or more fingers contracts toward the palm Limits range of motion and impairs quality of life Affects between 3-9% of adult Caucasians Pre-treatment: Post-treatment: Source: Endo Internati

  8. Slide 8: Peyronie's Disease

    XIAFLEX® for Peyronie’s Disease Definition & Key Complications Inelastic collagen causing penile curvature; penis can bend at 90° angle during erection in severe cases Associated with increased pain, painful erections, palpable plaque, penile deformity and erectile dysfunction Potential loss of self

  9. Slide 9: Pipeline Indications:

    XIAFLEX® Pipeline Indications:

  10. Slide 10: Uterine Fibroids

    XIAFLEX® for Uterine Fibroids Phase 1 Trial to Begin in 1Q17 Benign tumors in the reproductive tract that contain large amounts of collagen Definition & Key Cause pelvic discomfort and pain, decreased fertility, pregnancy Complications complications, increased rate of miscarriage, heavy menstrual bl

  11. Slide 11: Uterine Fibroids: Phase 1 Trial Design

    XIAFLEX® for Uterine Fibroids Phase 1 Trial Design Open-label dose escalation Phase 1 study in 15 female subjects treated prior to hysterectomy 3 groups Primary endpoint: Assess the safety and tolerability of CCH following a one-time injection directly into uterine leiomyomas at three doses under tr

  12. Slide 12: Cellulite: Results from Phase 2a Study

    XIAFLEX® for Cellulite Results from Phase 2a Study Overview Skin dimpling as a result of collagen fibrous septae, occurring mainly on the buttocks, lower limbs, and abdomen Affects ~85-98% of post-pubertal females Day 1 Day 73 Pre-Treatment 30 Days Following Last Treatment Source: Endo International

  13. Slide 13: Cellulite: Top-line Data from Phase 2b Study

    XIAFLEX® for Cellulite Highly Statistically Significant Top-line Data from Phase 2b Study 375 women with moderate or severe cellulite (18+ years) Up to 3 treatment sessions of 0.84 mg/session or placebo (12 injections per session) with each treatment session occurring 21 days apart Primary endpoint

  14. Slide 14: Adhesive Capsulitis

    XIAFLEX® for Adhesive Capsulitis Potential to be Only FDA Approved Nonsurgical Therapy Inflammation and thickening of shoulder capsule due to collagen Limits range of motion of shoulder Common available treatment options are often painful and can require anesthesia Long-term intensive physical thera

  15. Slide 15: Human Lipomas

    XIAFLEX® for Human Lipomas Potential to be Only FDA-Approved Pharmaceutical Therapy U.S. Market Opportunity Phase 2 Trial Desi Encapsulated deposits of benign fat, often detected as bulges under the skin No FDA-approved pharmaceutical therapies available Offers an alternative to patients that may ch

  16. Slide 16: Positive Top-Line Phase 2 Study Results

    Positive Top-Line Phase 2 Study Results Single 0.58 mg Injection of CCH Primary endpoint: 81.3% reduction in visible surface area for CCH vs. 2.1% increase for placebo; 83.4% difference in favor of CCH (p<0.0001) 89.5% responder rate (showed a >50% decrease in lipoma visible surface area relative to

  17. Slide 17: Lateral Hip Fat

    XIAFLEX® for Lateral Hip Fat Definition & Complications Similar prevalence to cellulite Fat accumulation is common among woman particularly as they age Often very difficult to improve its appearance through exercise and diet alone Patients frequently avoid exercise and are unable to restrict their c

  18. Slide 18: Plantar Fibromatosis

    XIAFLEX® for Plantar Fibromatosis Definition & Complications ~200,000 patients in the U.S. Pain and disability caused by the thickening of the feet's deep connective tissue Formation of nodules or cords along tendons of the foot Patients often have Dupuytren’s disease, ACR Peyronie’s disease and adh

  19. Slide 19: Additional Promising Unlicensed Indications

    Additional Promising Unlicensed Indications Capsular Contracture, Breast Hypertrophic Scars & Keloids Dercum’s Disease Knee Arthrofibrosis Urethral Strictures Source; Endo International ple Post-surgical complication that can deform the breast and cause pain Scars that form on the skin at site of in

  20. Slide 20: Endo Partnership for Development and Commercialization of XIAFLEX

    Endo Partnership for Development and Commercialization of XIAFLEX® >$101.7M Received as of September 30, 2016 Future Payments Due to BioSpecifics from Endo Endo Opt-in Rights Sublicense Income from Endo Partnerships $101.7M received in licensing, sublicensing, milestone, COGS, and royalty payments a

  21. Slide 21: Strong IP Portfolio

    Strong IP Portfolio Long-term patent protection for CCH Dupuytren’s Contracture Biologic Exclusivity until 2022 Drug product composition patent until 2028 Peyronie’s Disease Orphan Drug protection in U.S. until 2020 Drug product composition patent until 2028 Patents and Patent Applications Owned, co

  22. Slide 22: Consistently Profitable Annually

    Consistently Profitable Annually Financial Highlights (unaudited) For the nine months ended 09/30/16 09/30/15 7 Cash and equivalents, and investments $51,266,414 $ 32,824,471 Income Statement Revenues $19,630,307 $16,611,268 Other income 238,152 65,056 Costs and expenses (6,915,669) (6,062,469) Prov

  23. Slide 23: Anticipated Upcoming Pipeline Milestones

    Anticipated Upcoming Pipeline Milestones ENDO: Cosmetic Indications C1 Initiate Phase 3 clinical trial following positive top-line data from Phase 2b trial reported in Nov. 2016 Cellulite BIOSPECIFICS: Medically Necessary Indications Uterine Fibroids* C1 Initiate clinical trial in 1Q17

  24. Slide 24: Innovators in the development & commercialization of injectable collagenase

    ay Innovators in the development & commercialization of INJECTABLE COLLAGENASE tt BioSpecifics January 2017

Biospecifics Technologies — Investor Presentation (January 2017) on 6ix